Semiquantitation of mouse dendritic cell migration in vivo using cellular MRI

Gregory A. Dekaban, Jonatan Snir, Bradly Shrum, Sonali De Chickera, Christy Willert, Mia Merrill, Elias A. Said, Rafick Pierre Sekaly, Paula J. Foster, Peta J. O'Connell

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Despite recent therapeutic advances, including the introduction of novel cytostatic drugs and therapeutic antibodies, many cancer patients will experience recurrent or metastatic disease. Current treatment options, particularly for those patients with metastatic breast, prostate, or skin cancers, are complex and have limited curative potential. Recent clinical trials, however, have shown that cell-based therapeutic vaccines may be used to generate broad-based, antitumor immune responses. Dendritic cells (DC) have proved to be the most efficacious cellular component for therapeutic vaccines, serving as both the adjuvant and antigen delivery vehicle. At present it is not possible to noninvasively determine the fate of DC-based vaccines after their administration to human subjects. In this study, we demonstrate that in vitro-generated mouse DC can be readily labeled with superparamagnetic iron oxide nanoparticles, Feridex, without altering cell morphology, or their phenotypic and functional maturation. Feridex-labeling enables the detection of DC in vivo after their migration to draining lymph nodes using a 1.5áT clinical magnetic resonance scanner. In addition, we report a semiquantitative approach for analysis of magnetic resonance images and show that the Feridex-induced signal void volume, and fractional signal loss, correlates with the delivery and migration of small numbers of in vitro-generated DC. These findings, together with ongoing preclinical studies, are key to gaining information critical for improving the efficacy of therapeutic vaccines for the treatment cancer, and potentially, chronic infectious diseases.

Original languageEnglish
Pages (from-to)240-251
Number of pages12
JournalJournal of Immunotherapy
Volume32
Issue number3
DOIs
Publication statusPublished - Apr 2009

Fingerprint

Dendritic Cells
Cell Movement
Vaccines
Therapeutics
Magnetic Resonance Spectroscopy
Cancer Vaccines
Cytostatic Agents
Skin Neoplasms
Nanoparticles
Communicable Diseases
Prostatic Neoplasms
Chronic Disease
Lymph Nodes
Clinical Trials
Breast Neoplasms
Antigens
Antibodies
ferumoxides
Neoplasms

Keywords

  • Cancer
  • Dendritic cells
  • Immunotherapy
  • Magnetic resonance imaging
  • Vaccine

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Cancer Research
  • Pharmacology
  • Medicine(all)

Cite this

Dekaban, G. A., Snir, J., Shrum, B., De Chickera, S., Willert, C., Merrill, M., ... O'Connell, P. J. (2009). Semiquantitation of mouse dendritic cell migration in vivo using cellular MRI. Journal of Immunotherapy, 32(3), 240-251. https://doi.org/10.1097/CJI.0b013e318197b2a0

Semiquantitation of mouse dendritic cell migration in vivo using cellular MRI. / Dekaban, Gregory A.; Snir, Jonatan; Shrum, Bradly; De Chickera, Sonali; Willert, Christy; Merrill, Mia; Said, Elias A.; Sekaly, Rafick Pierre; Foster, Paula J.; O'Connell, Peta J.

In: Journal of Immunotherapy, Vol. 32, No. 3, 04.2009, p. 240-251.

Research output: Contribution to journalArticle

Dekaban, GA, Snir, J, Shrum, B, De Chickera, S, Willert, C, Merrill, M, Said, EA, Sekaly, RP, Foster, PJ & O'Connell, PJ 2009, 'Semiquantitation of mouse dendritic cell migration in vivo using cellular MRI', Journal of Immunotherapy, vol. 32, no. 3, pp. 240-251. https://doi.org/10.1097/CJI.0b013e318197b2a0
Dekaban GA, Snir J, Shrum B, De Chickera S, Willert C, Merrill M et al. Semiquantitation of mouse dendritic cell migration in vivo using cellular MRI. Journal of Immunotherapy. 2009 Apr;32(3):240-251. https://doi.org/10.1097/CJI.0b013e318197b2a0
Dekaban, Gregory A. ; Snir, Jonatan ; Shrum, Bradly ; De Chickera, Sonali ; Willert, Christy ; Merrill, Mia ; Said, Elias A. ; Sekaly, Rafick Pierre ; Foster, Paula J. ; O'Connell, Peta J. / Semiquantitation of mouse dendritic cell migration in vivo using cellular MRI. In: Journal of Immunotherapy. 2009 ; Vol. 32, No. 3. pp. 240-251.
@article{2d49d6d1c42543538ef2469f5c0e3df8,
title = "Semiquantitation of mouse dendritic cell migration in vivo using cellular MRI",
abstract = "Despite recent therapeutic advances, including the introduction of novel cytostatic drugs and therapeutic antibodies, many cancer patients will experience recurrent or metastatic disease. Current treatment options, particularly for those patients with metastatic breast, prostate, or skin cancers, are complex and have limited curative potential. Recent clinical trials, however, have shown that cell-based therapeutic vaccines may be used to generate broad-based, antitumor immune responses. Dendritic cells (DC) have proved to be the most efficacious cellular component for therapeutic vaccines, serving as both the adjuvant and antigen delivery vehicle. At present it is not possible to noninvasively determine the fate of DC-based vaccines after their administration to human subjects. In this study, we demonstrate that in vitro-generated mouse DC can be readily labeled with superparamagnetic iron oxide nanoparticles, Feridex, without altering cell morphology, or their phenotypic and functional maturation. Feridex-labeling enables the detection of DC in vivo after their migration to draining lymph nodes using a 1.5{\'a}T clinical magnetic resonance scanner. In addition, we report a semiquantitative approach for analysis of magnetic resonance images and show that the Feridex-induced signal void volume, and fractional signal loss, correlates with the delivery and migration of small numbers of in vitro-generated DC. These findings, together with ongoing preclinical studies, are key to gaining information critical for improving the efficacy of therapeutic vaccines for the treatment cancer, and potentially, chronic infectious diseases.",
keywords = "Cancer, Dendritic cells, Immunotherapy, Magnetic resonance imaging, Vaccine",
author = "Dekaban, {Gregory A.} and Jonatan Snir and Bradly Shrum and {De Chickera}, Sonali and Christy Willert and Mia Merrill and Said, {Elias A.} and Sekaly, {Rafick Pierre} and Foster, {Paula J.} and O'Connell, {Peta J.}",
year = "2009",
month = "4",
doi = "10.1097/CJI.0b013e318197b2a0",
language = "English",
volume = "32",
pages = "240--251",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Semiquantitation of mouse dendritic cell migration in vivo using cellular MRI

AU - Dekaban, Gregory A.

AU - Snir, Jonatan

AU - Shrum, Bradly

AU - De Chickera, Sonali

AU - Willert, Christy

AU - Merrill, Mia

AU - Said, Elias A.

AU - Sekaly, Rafick Pierre

AU - Foster, Paula J.

AU - O'Connell, Peta J.

PY - 2009/4

Y1 - 2009/4

N2 - Despite recent therapeutic advances, including the introduction of novel cytostatic drugs and therapeutic antibodies, many cancer patients will experience recurrent or metastatic disease. Current treatment options, particularly for those patients with metastatic breast, prostate, or skin cancers, are complex and have limited curative potential. Recent clinical trials, however, have shown that cell-based therapeutic vaccines may be used to generate broad-based, antitumor immune responses. Dendritic cells (DC) have proved to be the most efficacious cellular component for therapeutic vaccines, serving as both the adjuvant and antigen delivery vehicle. At present it is not possible to noninvasively determine the fate of DC-based vaccines after their administration to human subjects. In this study, we demonstrate that in vitro-generated mouse DC can be readily labeled with superparamagnetic iron oxide nanoparticles, Feridex, without altering cell morphology, or their phenotypic and functional maturation. Feridex-labeling enables the detection of DC in vivo after their migration to draining lymph nodes using a 1.5áT clinical magnetic resonance scanner. In addition, we report a semiquantitative approach for analysis of magnetic resonance images and show that the Feridex-induced signal void volume, and fractional signal loss, correlates with the delivery and migration of small numbers of in vitro-generated DC. These findings, together with ongoing preclinical studies, are key to gaining information critical for improving the efficacy of therapeutic vaccines for the treatment cancer, and potentially, chronic infectious diseases.

AB - Despite recent therapeutic advances, including the introduction of novel cytostatic drugs and therapeutic antibodies, many cancer patients will experience recurrent or metastatic disease. Current treatment options, particularly for those patients with metastatic breast, prostate, or skin cancers, are complex and have limited curative potential. Recent clinical trials, however, have shown that cell-based therapeutic vaccines may be used to generate broad-based, antitumor immune responses. Dendritic cells (DC) have proved to be the most efficacious cellular component for therapeutic vaccines, serving as both the adjuvant and antigen delivery vehicle. At present it is not possible to noninvasively determine the fate of DC-based vaccines after their administration to human subjects. In this study, we demonstrate that in vitro-generated mouse DC can be readily labeled with superparamagnetic iron oxide nanoparticles, Feridex, without altering cell morphology, or their phenotypic and functional maturation. Feridex-labeling enables the detection of DC in vivo after their migration to draining lymph nodes using a 1.5áT clinical magnetic resonance scanner. In addition, we report a semiquantitative approach for analysis of magnetic resonance images and show that the Feridex-induced signal void volume, and fractional signal loss, correlates with the delivery and migration of small numbers of in vitro-generated DC. These findings, together with ongoing preclinical studies, are key to gaining information critical for improving the efficacy of therapeutic vaccines for the treatment cancer, and potentially, chronic infectious diseases.

KW - Cancer

KW - Dendritic cells

KW - Immunotherapy

KW - Magnetic resonance imaging

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=67449096024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67449096024&partnerID=8YFLogxK

U2 - 10.1097/CJI.0b013e318197b2a0

DO - 10.1097/CJI.0b013e318197b2a0

M3 - Article

C2 - 19242376

AN - SCOPUS:67449096024

VL - 32

SP - 240

EP - 251

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 3

ER -